{"id":"NCT00623805","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer","officialTitle":"A Randomized, Multicenter Phase III Trial to Assess the Efficacy and Safety of Bevacizumab and Capecitabine as Maintenance Treatment, After Initial Combination Treatment With Capecitabine, Oxaliplatin and Bevacizumab in Patients With Metastatic Colorectal Adenocarcinoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-03","primaryCompletion":"2012-05","completion":"2012-05","firstPosted":"2008-02-26","resultsPosted":"2014-08-08","lastUpdate":"2014-08-08"},"enrollment":123,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Colorectal Cancer"],"interventions":[{"type":"DRUG","name":"Bevacizumab","otherNames":["Avastin"]},{"type":"DRUG","name":"Capecitabine","otherNames":["Xeloda"]},{"type":"DRUG","name":"Oxaliplatin","otherNames":["Eloxatin"]}],"arms":[{"label":"Bevacizumab+capecitabine+oxaliplatin","type":"ACTIVE_COMPARATOR"},{"label":"Bevacizumab(B)+capecitabine(C)+oxaliplatin followed by B+C","type":"EXPERIMENTAL"}],"summary":"This 2 arm study assessed the efficacy and safety of maintenance treatment with Avastin (bevacizumab) + Xeloda (capecitabine), after initial treatment with Xeloda + oxaliplatin + Avastin, in patients with metastatic colorectal cancer. Patients were randomized into one of 2 groups to receive 1) Xeloda + oxaliplatin + Avastin until disease progression or 2) Xeloda + oxaliplatin + Avastin for 6 3-week cycles, followed by Xeloda + Avastin until disease progression. Xeloda was administered at a dose of 1000 mg/m\\^2 orally twice a day on days 1-14 of each cycle, oxaliplatin at a dose of 130 mg/m\\^2 intravenously (iv) on day 1 of each cycle, and Avastin at a dose of 7.5 mg/kg iv on day 1 of each cycle.","primaryOutcome":{"measure":"Progression-free Survival","timeFrame":"Baseline to the end of the study (up to 4 years, 2 months)","effectByArm":[{"arm":"Bevacizumab+Capecitabine+Oxaliplatin","deltaMin":9,"sd":0.7},{"arm":"Bevacizumab(B)+Capecitabine(C)+Oxaliplatin Followed by B+C","deltaMin":12.6,"sd":1}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":10,"countries":["Turkey (TÃ¼rkiye)"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":62},"commonTop":["Neuropathy","Hemifacial spasm","Nausea","Weakness","Diarrhea"]}}